ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-5218ometendo-5218Research ArticleСтатьиArticlesБезопасность метформина с точки зрениягепатологаBezopasnost' metformina s tochki zreniyagepatologaBueverovA O-20101506201072№2 (2010)7376Copyright © Bueverov A.O., 20102010Bueverov A.O.Bueverov A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/5218ReferencesБайкова И.Е., Никитин И.Г. Лекарственное поражение печени // РМЖ, 2009; 11: 1-5.Байкова И.Е., Никитин И.Г. Лекарственное поражение печени // РМЖ, 2009; 11: 1-5.Буеверов А.О. Возможности лечения лекарственных поражений печени в условиях необходимости приема гепатотоксичных препаратов // Леч. врач, 2009; 2: 40-42.Буеверов А.О. Возможности лечения лекарственных поражений печени в условиях необходимости приема гепатотоксичных препаратов // Леч. врач, 2009; 2: 40-42.Буеверов А.О., Богомолов П.О. Неалкогольная жировая болезнь печени: обоснование патогенетической терапии // Клин. перспект. гастроэнтерол. гепа- тол., 2009; 1: 3-9.Буеверов А.О., Богомолов П.О. Неалкогольная жировая болезнь печени: обоснование патогенетической терапии // Клин. перспект. гастроэнтерол. гепа- тол., 2009; 1: 3-9.Демидова И.Ю., Горохова Т.В. Механизм действия и клиническое применение метформина (Сиофор®): обзор литературы // Фарматека, 2009; 17: 10-15.Демидова И.Ю., Горохова Т.В. Механизм действия и клиническое применение метформина (Сиофор®): обзор литературы // Фарматека, 2009; 17: 10-15.Adeneya A.A., Benebo A.S. Oral metformin-ascorbic acid coadministration ameliorates alcohol-induced hepatotoxicity in rats // Nig. Q. J. Hosp. Med., 2007; 17: 15-159.Adeneya A.A., Benebo A.S. Oral metformin-ascorbic acid coadministration ameliorates alcohol-induced hepatotoxicity in rats // Nig. Q. J. Hosp. Med., 2007; 17: 15-159.Caldwell S.H., Argo C.K., Al-Osaimi A.M. Therapy of NAFLD: insulin sensitizing agents // J. Clin. Gastroenterol, 2006; 40: 61-66.Caldwell S.H., Argo C.K., Al-Osaimi A.M. Therapy of NAFLD: insulin sensitizing agents // J. Clin. Gastroenterol, 2006; 40: 61-66.Desilets D.J., Shorr A.F., Moran K.A., Holtzmuller K.C. Cholestatic jaundice asoociated with use of metformin // Am. J. Gastroenterol., 2001; 96: 2257-2258.Desilets D.J., Shorr A.F., Moran K.A., Holtzmuller K.C. Cholestatic jaundice asoociated with use of metformin // Am. J. Gastroenterol., 2001; 96: 2257-2258.Kozka U., Holma G.D. Metformin blocks down-regulation of cell-surface GLUT4 caused by chronic insulin treatment of rat adipocytes // Diabetes, 1993; 42: 1159-1165.Kozka U., Holma G.D. Metformin blocks down-regulation of cell-surface GLUT4 caused by chronic insulin treatment of rat adipocytes // Diabetes, 1993; 42: 1159-1165.Krentz A.J. Comparative safety of newer oral antidiabetic drugs // Expert. Opin. Drug. Saf., 2006; 5: 827-834.Krentz A.J. Comparative safety of newer oral antidiabetic drugs // Expert. Opin. Drug. Saf., 2006; 5: 827-834.Kutoh E. Possible metformin-induced hepatotoxicity // Am. J. Geriatr. Pharmacother., 2005; 3: 270-273.Kutoh E. Possible metformin-induced hepatotoxicity // Am. J. Geriatr. Pharmacother., 2005; 3: 270-273.Marchesini G. Metformin in non-alcoholic steatohepatitis // Lancet, 2001; 358: 893-894.Marchesini G. Metformin in non-alcoholic steatohepatitis // Lancet, 2001; 358: 893-894.Matthaei S., Reibold J.P., Hamann A. et al. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes // Endocrinology, 1993; 133: 304-311.Matthaei S., Reibold J.P., Hamann A. et al. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes // Endocrinology, 1993; 133: 304-311.Nammour F.E., Fayad N.F., Peitcin S.R. Metformin-induced cholestatic hepatitis // Endocr. Pract., 2003; 9: 307-309.Nammour F.E., Fayad N.F., Peitcin S.R. Metformin-induced cholestatic hepatitis // Endocr. Pract., 2003; 9: 307-309.Poza-Gomes G., Rivero Fernandez F., Vaguez Romero M. et al. Constitutional syndrome associated to metformin induced hepatotoxicity // Gastroenterol. Hepatol., 2008; 31: 643-645.Poza-Gomes G., Rivero Fernandez F., Vaguez Romero M. et al. Constitutional syndrome associated to metformin induced hepatotoxicity // Gastroenterol. Hepatol., 2008; 31: 643-645.U.K. prospective diabetes study: intensive blood glucose control with sulphonylureas and insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS) // Lancet, 1998; 352: 837-853.U.K. prospective diabetes study: intensive blood glucose control with sulphonylureas and insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS) // Lancet, 1998; 352: 837-853.Urso R. Metformin in non-alcoholic steatohepatitis // Lancet, 2002; 359: 355-356.Urso R. Metformin in non-alcoholic steatohepatitis // Lancet, 2002; 359: 355-356.Zou M.H., Wu Y. AMP-activated proteine kinase activation as a strategy for protecting vascular endothelial function // Clin. Exp. Pharmacol. Physiol., 2008; 35: 535-545.Zou M.H., Wu Y. AMP-activated proteine kinase activation as a strategy for protecting vascular endothelial function // Clin. Exp. Pharmacol. Physiol., 2008; 35: 535-545.

The authors declare that there are no conflicts of interest present.